Live Breaking News & Updates on சித்தாந்த் கண்டெகர்
Stay updated with breaking news from சித்தாந்த் கண்டெகர். Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Anand Rathi said Glenmark Life has leadership in select high-value non-commercialized APIs in chronic therapeutic areas. It said the has cost leadership, a strong balance sheet, a growing business, and a high return on net worth (RoNW) of 46.71 per per cent. Add to that are reasonable valuations, which the brokerage said made it suggest a subscribe on the issue. Geojit Financial Services called the IPO fairly priced and suggested a Subscribe for a long-term basis, considering Glenmark s strong focus on research and development (R&D), its expansion plans, the growth opportunity ahead in CDMO (contract development and manufacturing operations) services and expanding of complex API portfolio. ....
Glenmark Life Sciences IPO opens tomorrow: Should you subscribe? indiatimes.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from indiatimes.com Daily Mail and Mail on Sunday newspapers.
Explore Now Mumbai: Punters are circling back to shares of companies that would benefit the most from the second wave of Covid-19. Many of these stocks had gone out of favour in recent months with the infections receding. Now, with the virus making a comeback, companies dealing in oxygen or medical equipment supplies, manufacturers of Covid-19 drugs, vaccine makers, and diagnostic centres among others are back in focus. ET has compiled a list of such stocks that are currently in the limelight. Cipla with nearly 50% market share of Remdesivir has doubled its production to meet incremental demand. This coupled with increase in production of vaccines will yield short- to medium-term benefits by way of higher revenues. “Cipla is well positioned to deliver strong earnings growth over the medium term with incremental respiratory launches/filings and continued execution in domestic business through its One India strategy,” said Kumar Gaurav, analyst, Kotak Securities. ....
Read more about Investors turn to pharma stocks amid market crash; Nifty Pharma gains 1.5% on Business Standard. Among individual stocks, Lupin zoomed 3.4 per cent in the intra-day trade and hit a high of Rs 1,060, Sun Pharmaceuticals advanced 2 per cent, and Dr Reddy s Labs gained 1.7 per cent. ....
Union Budget 2021, which was presented amid a global health crisis, was sketched with 6 pillars in focus. Among these, healthcare was the foremost agendum of Finance Minister Nirmala Sitharaman’s Budget speech, and the sector was allocated a generous pie of the entire budgetary allocation. At Rs 223,846 crore, the sector s allocation jumped around 118 per cent over the Revised Estimate of the current fiscal year. Yet, stocks from the sector have been underwhelming at the bourses. The S&P BSE Healthcare index is up just 1 per cent on the BSE today, at 20,891.5 levels, as against an over 2 per cent gain in the S&P BSE Sensex. In the past two days, the Sensex index has jumped nearly 4,000 points or 7.2 per cent, compared with the Healthcare index’s 1.2 per cent gain. ....